Devil in the detail: MET overexpression fails as surrogate marker for MET exon 14 splice site mutations in NSCLC

類似資料

• A Concise Review of the Approved MET TKIs (Savolitinib, Gumarontinib, Vebreltinib, Tepotinib, Capmatinib) in China for MET Exon 14 Splice Site Mutated (METex14+) NSCLC Circa 2025
  著者:: Hu Y, 等
  出版事項: (2025-10-01)
• Activity and bioavailability of tepotinib for leptomeningeal metastasis of NSCLC with MET exon 14 skipping mutation
  著者:: Tanaka, Hisashi, 等
  出版事項: (2021)
• MET exon 14 juxtamembrane splicing mutations: clinical and therapeutical perspectives for cancer therapy
  著者:: Pilotto, Sara, 等
  出版事項: (2017)
• Capmatinib in Japanese patients with MET exon 14 skipping–mutated or MET‐amplified advanced NSCLC: GEOMETRY mono‐1 study
  著者:: Seto, Takashi, 等
  出版事項: (2021)
• Mutations at the splice sites of exon 14 of MET gene: a new target for sarcomatoid carcinomas?
  著者:: Wislez, Marie, 等
  出版事項: (2016)